First report of vancomycin-intermediate resistance in sequence type 72 community genotype methicillin-resistant Staphylococcus aureus.

Journal of Clinical Microbiology
Doo Ryeon ChungJae-Hoon Song

Abstract

Vancomycin-intermediate resistance has not been previously reported among sequence type 72 (ST72) methicillin-resistant Staphylococcus aureus (MRSA) isolates of SCCmec type IV (ST72-MRSA-IV), which are distinctive community genotype strains in Korea. We report the first case of vancomycin treatment failure due to development of vancomycin-intermediate resistance in infection caused by an ST72-MRSA-IV isolate.

References

Jul 1, 1997·The Journal of Antimicrobial Chemotherapy·K HiramatsuF C Tenover
Oct 19, 1999·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·G LinaJ Etienne
Oct 4, 2000·Journal of Clinical Microbiology·M N KimK Hiramatsu
Feb 5, 2003·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Scott K FridkinUNKNOWN Vancomycin-Intermediate Staphylococcus aureus Epidemiology Study Group
Jan 27, 2006·Antimicrobial Agents and Chemotherapy·Longzhu CuiKeiichi Hiramatsu
Jun 8, 2007·Emerging Infectious Diseases·Christopher J GraberHenry F Chambers
Oct 10, 2008·Diagnostic Microbiology and Infectious Disease·Jeffrey C HagemanFazle N Khan
Mar 12, 2011·The Journal of Antimicrobial Chemotherapy·Jae-Hoon SongUNKNOWN ANSORP Study Group

❮ Previous
Next ❯

Citations

Jul 24, 2013·Diagnostic Microbiology and Infectious Disease·Xia ZhangXiancai Rao
Jun 9, 2017·The Journal of Antimicrobial Chemotherapy·Jin Yang BaekJae-Hoon Song
Jun 22, 2018·Microbial Drug Resistance : MDR : Mechanisms, Epidemiology, and Disease·Gi Yong LeeSoo-Jin Yang
Sep 21, 2016·Expert Review of Anti-infective Therapy·Kyungmin Huh, Doo Ryeon Chung

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.